Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

8.75USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$8.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,907
52-wk High
$9.90
52-wk Low
$2.77

Chart for

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)
No analyst recommendations are available for .

Overall

Beta: 1.59
Market Cap(Mil.): $140.35
Shares Outstanding(Mil.): 16.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-GTx announces positive results from enobosarm Phase 2 proof-of-concept clinical trial

* GTx announces positive results from enobosarm phase 2 proof-of-concept clinical trial in women with stress urinary incontinence

Sep 13 2017

BRIEF-GTx Q2 loss per share $0.40

* Gtx provides corporate update and reports second quarter 2017 financial results

Aug 14 2017

BRIEF-GTX announces positive preliminary results from ongoing trial in women with stress urinary incontinence

* GTX announces positive preliminary results from ongoing phase 2 proof-of-concept clinical trial in women with stress urinary incontinence

Jun 12 2017

BRIEF-GTX reports Q1 net loss per share of $0.39

* GTX provides corporate update and reports first quarter 2017 financial results

May 15 2017

Earnings vs. Estimates